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ABSTRACT 
Objective: To compile an inventory of European healthcare databases with potential to 
study long-term effects of methylphenidate (MPH) in patients with attention deficit 
hyperactivity disorder (ADHD). Method: Potential databases were identified through expert 
opinion, the website of the European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance, and literature search.  An online survey was conducted among database 
providers/coordinators to ascertain the databases’ appropriateness for inclusion into the 
inventory.  It included questions about database characteristics, sample size, availability of 
information on drug exposure, clinical data, and accessibility. Results: Forty-two databases 
from 11 countries were identified and their coordinators invited to participate; responses 
were obtained for 22 (52.4%) databases of which 15 record ADHD diagnoses. Eleven had 
sufficient data on ADHD diagnosis, drug exposure, and at least one type of outcome 
information (symptoms/clinical events, weight, height, blood pressure, heart rate) to assess 
MPH safety. These were: Aarhus University Prescription Database, Danish National Birth 
Cohort (Denmark); German Health Interview and Examination Survey for Children and 
Adolescents; Health Search Database Thales, Italian ADHD Register, Lombardy Region ADHD 
Database (Italy); Avon Longitudinal Study of Parents and Children, General Practice Research 
Database, The Health Improvement Network, QResearch (UK); IMS Disease Analyzer (UK, 
Germany, France).  Of 20 databases with no responses, information on seven from 
publications and/or websites was obtained; Pedianet and the Integrated Primary Care 
Information Database were considered suitable. Conclusion: Many European healthcare 
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databases can be used for multinational long-term safety studies of MPH. Methodological 
research is underway to investigate the feasibility of their pooling and analysis.  
Keywords: Database(s); Methylphenidate; Attention Deficit Hyperactivity Disorder (ADHD); 
Drug Safety; Paediatric 
BACKGROUND 
As a first-line pharmacological therapy for attention deficit hyperactivity disorder (ADHD), 
methylphenidate (MPH) is widely prescribed in children and adolescents, and to a lesser 
extent to adults. The efficacy of MPH in ADHD has been robustly demonstrated in 
randomised controlled trials with approximately 70% of children, adolescents and adults 
showing a therapeutic response [1]. Other effective drugs for ADHD are the potent 
psychostimulant dexamfetamine, and atomoxetine, a selective noradrenaline reuptake 
inhibitor.  Although the medications for ADHD are generally well-tolerated, commonly 
reported adverse effects include neurological effects (such as headache, insomnia), 
gastroenterological effects (loss of appetite, nausea and vomiting, abdominal pain), 
psychiatric effects (mood, anxiety), and chronic effects such as growth restriction and 
increases in blood pressure [2,3].  In order to control the acute and chronic adverse effects 
of medication, often patients on long-term (>1 year) drug treatment have a structured 
interruption of treatment (known as a drug holiday). This allows monitoring to ensure 
medication is still effective, and assessment of whether the balance between adverse 
effects and therapeutic effects favours the continuation of treatment [3].  
In 2006, there were safety concerns reported about the use of amfetamines and MPH as 
treatments for ADHD, specifically with respect to cardiovascular safety of these products [4]. 
In 2007, the European Commission requested a referral to the Committee for Medicinal 
Products for Human Use (CHMP) under Article 31 of Directive 2001/83/EC, as amended, for 
MPH because of safety concerns [5]. The CHMP concluded that insufficient was known 
about the long-term adverse effects of MPH on growth, sexual development, the 
neurological system, psychiatric states and the cardiovascular system, and further 
assessment is needed. In January 2009, the European Medicines Agency (EMA) concluded 
that the benefit-risk ratio of methylphenidate in the authorised indication remains 
favourable but more data are needed on the long-term effects in children, adolescents and 
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young adults [6]. In response to the CHMP’s concerns, the ADDUCE (Attention Deficit 
Hyperactivity Disorder Drugs Use Chronic Effects) research team was formed by a 
consortium of experts in the fields of ADHD, drug safety, neuro-psychopharmacology and 
cardiovascular research. The ADDUCE project, funded under the European Union’s 7th 
Framework Programme, will use pharmacoepidemiological research methods to investigate 
the long-term adverse effects of MPH on growth, the neurological system (including 
cognition and motivation), psychiatric states and the cardiovascular system in children, 
adolescents and adults. The methodologies employed will be: the acquisition and analysis of 
existing patient databases; a two-year prospective cohort study of MPH-treated patients 
and two control groups; and a cross-sectional study in late adolescents and young adults.  A 
methodological overview of the ADDUCE project is provided by the website (http://adhd-
adduce.org). 
Electronic health care databases, comprising patient data, drug prescription data, patient 
outcomes, and information on confounding variables, potentially provide valuable resources 
to examine associations between drug use and long-term adverse effects. A survey 
published in 2008 showed that many European healthcare databases had enormous 
potential for use in paediatric drug utilisation and safety studies [7]. The use of electronic 
health records was also recommended by the EMA when conducting post-authorisation 
drug utilisation and safety studies [8]. 
Previous studies have demonstrated that healthcare databases can be used to investigate 
certain adverse effects of MPH. Gau et al. used the National Health Insurance database 
(Taiwan) to assess the association between MPH use and psychiatric disorders in 2,109 
children and adolescents with new onset ADHD between 1999 and 2003 matched 1:4 with 
non-ADHD controls. In this study, MPH use was associated with the occurrence of bipolar 
disorder (adjusted hazard ratio (HR), 4.1; 95% CI: 1.7, 9.7, p<0.05) [9]. McCarthy et al. aimed 
to estimate the mortality rates associated with stimulant and non-stimulant treatment 
prescription using the UK General Practice Research Database (GPRD). Compared with the 
general population, there was a 162-fold increased risk of completed suicide in patients 
aged 11-14 years using psychostimulants or atomoxetine (standardized mortality ratio: 
161.91 [95% CI: 19.61, 584.88]) [10].  Recently, four large US health-plan databases of 
insurance claims were combined to assess the use of ADHD drugs and the risk of serious 
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cardiovascular events (sudden cardiac death, myocardial infarction, stroke) in children and 
young adults [11]. A total of 81 serious cardiovascular events were confirmed from over 2.5 
million person-years of follow-up giving an incidence of 3.1 events per 100,000 person-years 
in the study cohort. Among current users of ADHD drugs there was no increased risk of 
serious cardiovascular events when compared with non-users (adjusted HR, 0.75; 95% CI: 
0.31, 1.85), and there was no evidence of increased risk for methylphenidate (adjusted HR, 
0.96; 95% CI: 0.31, 2.97).  Another study of claims data (Medicaid) from 28 US states found 
that the treatment of children aged 3-18 years with MPH or mixed amfetamine salts was not 
significantly associated with an increased short-term risk of severe cardiac events [12]. 
However both US studies were unable to assess the long-term safety of stimulant treatment 
due to their short follow-up of two years [11,12]. 
On the basis of these examples we judged that analysis of existing health care databases 
might be useful to study the association between MPH use and long-term adverse events. 
Although this might not be possible for all adverse events of interest (e.g. sleep 
abnormalities), such databases may provide important health information relevant for the 
systematic study of side effects. However, many studies performed in Europe have been 
limited in their power and scope by the use of a single data source. Cooper et al. 
demonstrated the value of using multiple existing databases in the US to obtain large 
sample sizes to study the safety of ADHD drugs [11]; adopting a similar approach in Europe 
may be valuable if the issues concerning the pooling of such databases could be overcome. 
Our previous work has shown this to be feasible [13-16].  Hence the aim of this study is to 
compile an inventory of existing European databases which can be used to study the effects 
of long-term MPH use in patients with ADHD. 
METHODS 
There were a number of steps taken to achieve our aim.  
First, a list of all known potentially relevant European databases with individual patient 
information was collated. A range of different methods were used to identify eligible 
databases: from those listed on the website of the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP); a systematic review of the 
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published literature (including conference proceedings [17]) and finally, by nominations 
from members of the ADDUCE Consortium. 
Second, a questionnaire comprising 33 questions to collect detailed database information 
was designed (by SI, TB, MLM, SM, AN, and ICKW) and implemented using a web-based data 
collection tool (SurveyMonkeyTM). A request to complete the questionnaire survey was sent 
to the providers/coordinators of the identified databases.  Information collected on each 
database comprised: general information on the database (name, country); a description of 
the nature of the database (e.g. longitudinal/patient record database, disease registry, 
cross-sectional, observational data survey); characteristics and sample size (such as number 
of investigators, database starting date, and number of patients); availability of data on the 
exposure to medication and on symptoms and clinical events; and accessibility.  Examples of 
questions are: “Is information available on ADHD diagnosis?”; “Which of the following data 
are recorded in the database? Weight, height, blood pressure, heart rate”; “What system is 
used to code diagnoses?” 
Third, databases were categorised with respect to their potential suitability for investigating 
the long-term safety of MPH based on the availability of individual patient information. Our 
criteria were based on the basic data elements that are required for 
pharmacoepidemiologic research using healthcare databases [18].  To be useful for the 
investigation of the long-term safety of MPH use for ADHD, databases had to record 
information about the following clinical aspects of individual patients: ADHD diagnosis, MPH 
exposure (dose and duration), exposure to other medications, potential adverse outcomes 
(such as effects on height and weight, blood pressure, heart rate) and other 
symptoms/clinical events.  Furthermore, information on the structure and standardisation 
of data, costs to access the database, completeness of clinical and drug information, and 
previous applications in research or validation studies were considered. The ability to 
combine with data from other sources was also assessed based on whether the database 
used unique patient identifiers (to allow for record linkage), and coding systems for 
diagnoses, clinical events and medications prescribed. 
Last, detailed information of all databases without survey responses were sought from 
publications and the websites of their data providers/coordinators. Where possible, 
Verwijderd: , and other 
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information collated was based on that requested in the survey questions. The databases 
were then assessed for their potential suitability using similar criteria to those used above.  
RESULTS 
Response to the survey 
Forty-two databases from 11 European countries were identified and their 
providers/coordinators were invited to participate in the survey (Figure 1).  Responses were 
obtained from 22 (52.4%) database coordinators/providers in 7 European countries (Table 
1). Seven of these 22 databases did not contain information on ADHD diagnosis; therefore 
15 databases were included in the detailed assessment. Table 2 provides detailed 
information of the participating databases. Only one database had an incomplete response 
to the survey (Generation R study), however it was possible to obtain some of the missing 
details from the literature [19,20]. There was information on over 4.5 million children and 
adolescents in these 15 databases (of which just over 23,000 from 6 databases are reported 
to have ADHD); this is an overestimate due to the possibility that patients and/or their 
clinicians can contribute information to more than one database. For example, there is an 
overlap between GPRD and The Health Improvement Network (THIN) where 66% of 
contributing practices in THIN also contribute to GPRD between 2001 and 2008 [21]. 
Type of database 
Most of the selected databases are longitudinal/patient record databases (n=11). Two are 
ADHD-specific patient cohorts (Lombardy Region ADHD Database, and the Italian ADHD 
Register). One is a prescription information database (Aarhus University Prescription 
Database) and one is a cross-sectional, observational data survey (German Health Interview 
and Examination Survey for Children and Adolescents; KiGGS). Three databases could be 
linked to various other registries through unique patient identifiers (Aarhus University 
Prescription Database, Swedish National Health Data Registers and the National Psychiatric 
Central Register).  The purpose of data collection of the majority of databases was for 
patient management and disease surveillance (n=10); the remaining five are research 
cohorts: Danish National Birth Cohort (DNBC), KiGGS, Generation R Study, Dutch Child, 
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Parent and health: Lifestyle and Genetic constitution (KOALA) Birth Cohort Study, and Avon 
Longitudinal Study of Parents and Children (ALSPAC).  
Drug exposure 
Almost all databases contain information on prescribed medicines; Generation R Study does 
not collect details on prescriptions or drug exposure. One (Lombardy Region ADHD 
Database) has information on MPH and atomoxetine only. Most (n=14) include information 
on medical diagnosis and the indication for prescription drugs. Four (National Psychiatric 
Central Register, Generation R study, Swedish National Health Data Registers, and ALSPAC) 
contain limited information on dosage and duration of treatment. The Anatomical 
Therapeutic Chemical classification system (ATC) is commonly used to classify medications; 
10 of the 15 databases use this coding scheme [22,23]. Multilex is a UK drug terminology 
system used to classify medications and is used in the GPRD and THIN databases. Only one 
database (KOALA) currently does not use a medication coding system. 
Clinical outcomes 
Full clinical data (symptoms and clinical events, weight and height, blood pressure and heart 
rate) are available in 8 databases (KiGGS, Italian ADHD Register, Lombardy Region ADHD 
register, KOALA, ALSPAC, GPRD, THIN, and IMS Disease Analyzer [IMS DA]). The 
International Classification of Diseases 10th Revision (ICD-10) is used as the 
diagnoses/clinical event coding system in 6 databases (Aarhus University Prescription 
Database, DNBC, National Psychiatric Central Register, Swedish National Health Data 
Registers, ALSPAC, and IMS DA) [24]. Read Clinical Terms (a UK hierarchical classification 
system) is used in 4 UK databases (GPRD, THIN, QResearch, and IMS DA). One database, 
Health Search Database Thales (HSD), uses ICD-9 to code diagnoses and clinical events. 
Other variables 
The diagnostic process for ADHD and hyperkinetic disorder includes the recognition of 
specific behavioural and attentional symptoms per criteria of either the DSM-IV (Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition) [25] or ICD-10. However, these 
symptoms are also found in disorders other than ADHD [26,27].  Therefore, information on 
whether the ADHD diagnosis had been validated is important. For 2 databases (Italian ADHD 
Verwijderd:  (HSD)
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Register and Lombardy Region ADHD Database) clinicians use DSM-IV criteria to confirm 
diagnoses. In DNBC and KiGGS, ADHD diagnosis is supported by the scores from Strengths & 
Difficulties Questionnaire (SDQ) [28] which has a scale measuring ADHD symptoms. 
Questionnaires to general practitioners (GPs) can be used to obtain further information on 
diagnosis in the GPRD and THIN databases. 
Nine databases include information on ethnicity. Three databases (DNBC, National 
Psychiatric Central Register, and ALSPAC) also collect genetic information. 
Previous applications of databases in the field of research in paediatrics and/or ADHD 
The Italian ADHD Register has been previously used in studies on medication safety in ADHD 
patients.[29,30-31] The GPRD and THIN databases have been used to study the safety and 
use of ADHD drug treatment [10,32,33].  Data from KiGGS has been used in a number of 
paediatric studies, including those investigating the prevalence of mental health disorders, 
such as ADHD, and drug treatment [34,35]. ALSPAC has been widely studied and has 
numerous publications in paediatric research but none in ADHD.  
Data access 
All databases apart from one can be accessed either by paying a fee and/or via academic 
collaboration.  Nine of them (DNBC, National Psychiatric Central Register, KiGGS, HSD, 
Lombardy Region ADHD Database, KOALA, Swedish National Health Data Registers, ALSPAC, 
IMS DA) can be accessed via academic collaboration. The means to access the Aarhus 
University Prescription Database was not reported in the survey but the literature states 
project-specific permission from the Danish Data Protection Agency is required, and any 
data-linkage studies (which would be necessary to obtain outcome data) need approval 
from the Danish National Board of Health [36].  
Assessment of non-responding databases  
We obtained information on seven additional databases whose coordinators did not reply to 
the survey. These were: Prescription Register (Finland), The Finish Northern Finland Birth 
Cohort (NFBC) 1986 study, The German Population Based Long Term Follow-up of ADHD, 
Pedianet (Italy), Integrated Primary Care Information Database (IPCI; Netherlands), The 
Verwijderd: s
Verwijderd: a study
Verwijderd: Ten 
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1970 British Cohort Study, and The Millennium Cohort Study (UK). These databases were 
appraised using the same criteria as above with information obtained from database 
websites and published literature (Table 3).  
Type of database 
Three of these seven databases are longitudinal/patient record databases (the German 
Population Based Long Term Follow-up of ADHD, Pedianet and IPCI). Three are longitudinal 
birth cohorts (NFBC, the 1970 British Cohort Study, and The Millennium Cohort Study). Only 
one database is a prescription information database (Prescription Register (Finland)). 
Drug exposure 
Only two of the databases include information on indication of prescription and/or medical 
diagnosis (Pedianet and IPCI). Information on dosage and duration of prescription is 
available in Pedianet and IPCI, and both use the WHO ATC classification system [22]. 
Clinical outcomes 
Information on weight and height is found in Pedianet, IPCI, the 1970 British Cohort Study, 
and the Millennium Cohort Study. Two databases provide information on medical diagnosis 
and symptoms/clinical events (Pedianet and IPCI). Only IPCI classifies diagnoses/clinical 
events using the International Classification of Primary Care (ICPC) code [37]. 
Other variables, previous applications in research, and data access 
Due to limited information on these databases, the availability of data on confounding 
variables and data accessibility cannot be assessed. There is one study using Pedianet to 
investigate the safety of paediatric drugs [38].  No studies of paediatric drug safety using the 
IPCI database could be identified in the literature. However both databases have been 
previously used to study paediatric drug use [13-16]. A study describing the incidence and 
prevalence of ADHD and drug treatment for ADHD using The German Population Based Long 
term Follow-Up of ADHD database has been conducted [39]. 
Verwijderd: Confounding 
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Selection of Data source inventory 
According to our criteria for suitability, 11 of the 15 responding databases were considered 
to have potential value for the long-term safety evaluation of MPH. These are: Aarhus 
University Prescription Database, DNBC, KiGGS, HSD, Italian ADHD Register, Lombardy 
Region ADHD Database, ALSPAC, GPRD, THIN, QResearch, and IMS DA. Of the non-
responding databases, Pedianet and IPCI were considered potentially suitable. Hence, 13 
databases were included in our data source inventory. 
DISCUSSION 
From our survey we identified 13 sources of electronic health care records in Europe which 
have potential value in investigating the long-term effects of MPH treatment in patients 
with ADHD. These databases were selected because they record basic data elements 
required to conduct drug safety studies; these include: validated ADHD diagnosis (or at least 
the ability to confirm diagnosis), other diagnoses and clinical events, exposure to MPH, and 
exposure to any other medications, and potential adverse clinical outcomes. These data are 
rich resources, easily accessible, sourced from real-life practice, with the potential to 
provide large study populations for the long-term safety evaluation of MPH. Many are 
longitudinal in nature, which is essential for the long-term follow-up of patients. 
However, it is generally recognised that existing sources of data (including those we have 
identified) may have several limitations such as: selection bias, lack of control or comparison 
group, missing data (or limited detailed clinical information) [18], small sample sizes, and 
issues of quality control in data collection.  For example, the selection of an un-medicated 
group of ADHD patients from the 13 data cohorts may be challenging due to the small 
numbers of patients that exist (and would also affect prospective cohort studies). Some data 
may be unrecorded because the purpose of the database did not require it, such as details 
of pubertal maturation, specific psychiatric rating scales, measurements of brain function 
and activity (EEG, fMRI), or risk factors such as developmental history, parental history of 
medical and psychiatric problems, and life events. Other data may not be routinely entered 
at specific time intervals (e.g. height, weight, blood pressure, heart rate). Missing data may 
restrict the ability of some data sources to be used to study specific long-term effects (such 
as developmental or psychiatric effects), or even threaten the reliability and validity of 
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results, especially if confounding variables are unavailable. Misclassified diagnoses or 
outcomes can also affect the validity of a study. The issue of small sample sizes could be 
overcome if data are pooled to form larger cohorts.  These issues are not pertinent to all of 
the selected data sources in our inventory, but they all should be carefully considered (and 
addressed) when selecting data sources for our drug safety research. 
After consideration of these general limitations, the ADDUCE Consortium proposed that 
high quality data should be collected in a large prospective cohort study of patients with 
ADHD and their controls. This cohort study would collect specific information at set time 
points on efficacy measures of MPH, growth, coordination, psychiatric effects (using rating 
scales such as DAWBA – Developmental and Wellbeing Assessment modules), neurological 
effects (rating scales, measures of brain function and activity), as well as patient 
demographics, family and personal medical, psychiatric and medication histories, and 
physical examinations (including cardiac examinations). Much of these data are not 
recorded in the existing data sources of our inventory. However, there are also limitations 
to primary data collection of a large prospective cohort; it is time- and resource-consuming, 
and recruitment of a sufficiently large sample size to allow the study of rare effects of MPH 
may be difficult. Hence studies of large existing databases (single or pooled) in our inventory 
would complement those of the prospective cohort.  
There are opportunities to exploit the databases that we have identified in our inventory; in 
particular the combination of healthcare databases can potentially generate sample sizes 
and statistical power for large-scale drug safety studies [7]. European colleagues have 
recently pooled eight existing electronic healthcare databases covering four countries to 
generate an early signal detection system by creating a database platform using a common 
data framework (EU-ADR) [40]. The different clinical terminologies of the databases (e.g. 
Read Clinical Terms, ICD-9) can be mapped using a biomedical terminology integration 
system, Unified Medical Language System®. This generated a study population of almost 20 
million individuals with just under 60 million person years of data. Five of these databases 
are included in our inventory (Aarhus University Prescription Database, HSD, QResearch, 
Pedianet and IPCI) [40].  However, the amalgamation of existing databases is complex and 
goes beyond issues of data structures and sources. There are ethical issues concerning the 
processing of anonymised healthcare data, and national diversity in healthcare provision 
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and practice.[7,40] Also, some of the limitations described above such as the issue of data 
quality still remain, which affect the choice of analytical methods. Database providers may 
wish to improve the quality and completeness of recording by the end-user and increase the 
availability of more specific detailed clinical information (such as the results of diagnostic 
tests) [18] in order to enhance the research value of their databases. Despite the complexity 
of such a task, the EU-ADR project [40] and other studies [11] demonstrate that combining 
diverse databases of heterogeneous populations is feasible for drug safety research, with 
vast potential for further work. 
CONCLUSION 
There are 13 European databases of birth cohorts or electronic healthcare records included 
in the ADDUCE data inventory which have potential value individually or pooled for the 
evaluation of the long-term safety of MPH treatment in patients with ADHD. They are rich 
sources of data from real-life settings, and easily accessible. However, there are limitations 
in utilising existing sources of data including small sample sizes, missing data and poor data 
quality. The pooling of existing data sources presents opportunities for large-scale safety 
studies of MPH in the future; its feasibility is currently under investigation but data quality 
and analysis, ethical issues and national differences in healthcare provision need to be 
considered.  
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College London, UK), S. Evans (London School of Hygiene and Tropical Medicine, UK), A. 
Bilbow (ADDISS, London, UK). 
  
ADHD Data Inventory manuscript draft version 2.2: 24/12/2012 
Page 16 of 26 
REFERENCES 
1. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, Doyle AE. (2000) 
Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 48 (1):9-
20. 
2. Graham J, Coghill D. (2008) Adverse effects of pharmacotherapies for attention-deficit 
hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 
22(3):213-37. 
3. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner 
M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, 
Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, 
Steinhausen HC, Taylor E; European Guidelines Group. (2011) European guidelines on 
managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 
20(1):17-37. 
4. Nissen SE. (2006) ADHD drugs and cardiovascular risk. N Engl J Med 354 (14):1445-1448.  
5. European Medicines Agency. (2007) PRESS RELEASE: Meeting highlights from the 
Committee for Medicinal Products for Human Use, 16-19 July 2007. London: European 
Medicines Agency. 
http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/12/
WC500017068.pdf. Accessed 12 September 2012. 
6. European Medicines Agency. (2009) European Medicines Agency makes 
recommendations for safer use of Ritalin and other methylphenidate-containing 
medicines in the EU. London: European Medicines Agency. 
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/W
C500014589.pdf (accessed 12/09/2012). 
7. Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Nicolosi A, Giaquinto C, Ceci 
A, Wong IC. (2008) Databases for pediatric medicine research in Europe--assessment 
and critical appraisal. Pharmacoepidemiol Drug Saf 17 (12):1155-1167.  
8. European Medicines Agency. (2005) Guideline on Risk Management Systems for 
Medicinal Products for Human Use. London: European Medicines Agency. 
ADHD Data Inventory manuscript draft version 2.2: 24/12/2012 
Page 17 of 26 
9. Gau C-S, Chen C-F, Gau SS-F. (2010) The Influence of Using Methylphenidate on the 
Coming up of Psychiatric Disorders in Children with ADHD. Pharmacoepidemiol Drug Saf 
19(S1): S152-S153. 
10. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. (2009) Mortality associated with 
attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort 
study of children, adolescents and young adults using the general practice research 
database. Drug Saf 32 (11):1089-1096. 
11. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn 
VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray 
WA. (2011) ADHD drugs and serious cardiovascular events in children and young adults. 
N Engl J Med 365(20):1896-904. 
12. Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson 
M. (2012) Cardiovascular safety of central nervous system stimulants in children and 
adolescents: population based cohort study. BMJ 345:e4627. doi: 10.1136/bmj.e4627. 
13. Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Sen F, Giaquinto C, 
Ceci A, Wong IC; on behalf of the TEDDY Network of Excellence. (2010) Comparison of 
antiepileptic drug prescribing in children in three European countries. Epilepsia 
51(5):789-96. 
14. Sen EF, Verhamme KM, Neubert A, Hsia Y, Murray M, Felisi M, Giaquinto C, 't Jong GW, 
Picelli G, Baraldi E, Nicolosi A, Ceci A, Wong IC, Sturkenboom MC; on behalf of the 
TEDDY European Network of Excellence. (2011) Assessment of Pediatric asthma drug 
use in three European countries; a TEDDY study. Eur J Pediatr 170(1):81-92. 
15. Neubert A, Verhamme K, Murray ML, Picelli G, Hsia HF, Sen FE, Giaquinto C, Ceci A, 
Sturkenboom M, Wong ICK. (2010) The Prescribing of Analgesics and Non-Steroidal 
Anti-Inflammatory Drugs in Paediatric Primary Care in the UK, Italy and the Netherlands. 
Pharmacological Research 62(3):243-8. 
16. Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, Picelli G, 
Sen EF, Giaquinto C, Cantarutti L, Baiardi P, Felisi MG, Ceci A, Wong IC; TEDDY European 
Network of Excellence. (2008) Drug use in children: cohort study in three European 
countries. BMJ 337:a2245. doi: 10.1136/bmj.a2245. 
ADHD Data Inventory manuscript draft version 2.2: 24/12/2012 
Page 18 of 26 
17. Anon. (2010) Abstracts of the 26th International Conference on Pharmacoepidemiology 
& Therapeutic Risk Management, 19-22 August 2010, Brighton, UK. Pharmacoepidemiol 
Drug Saf 19(S1): S1-S347. 
18. Schneeweiss S, Avorn J. (2005) A review of uses of health care utilization databases for 
epidemiologic research on therapeutics. J Clin Epidemiol 58: 323-337. 
19. Jaddoe VW, van Duijn CM, van der Heijden AJ, Mackenbach JP, Moll HA, Steegers EA, 
Tiemeier H, Uitterlinden AG, Verhulst FC, Hofman A. (2010) The Generation R Study: 
design and cohort update 2010. Eur J Epidemiol 25(11):823-41.  
20. Ghassabian A, Bongers-Schokking JJ, de Rijke YB, van Mil N, Jaddoe VW, de Muinck 
Keizer-Schrama SM, Hooijkaas H, Hofman A, Visser W, Roman GC, Visser TJ, Verhulst 
FC, Tiemeier H. (2012)  Maternal thyroid autoimmunity during pregnancy and the 
risk of attention deficit/hyperactivity problems in children: the Generation R Study.  
Thyroid 22(2):178-186. doi: 10.1089/thy.2011.0318.  
21. Cai B, Xu W, Bortnichak E, Watson D. (2012) An algorithm to identify medical practices 
common to both the General Practice Research Database and The Health Improvement 
Network database. Pharmacoepidemiol Drug Saf 21:770-774. 
22. WHO Collaborating Centre for Drug Statistics Methodology. (2012) Anatomical 
Therapeutic Chemical classification system: structure and principles.  
http://www.whocc.no/atc_ddd_index/. Accessed 15 August 2012. 
23. European Pharmaceutical Marketing Research Association (2012). Anatomical 
Classification.  http://www.ephmra.org/classification/anatomical-classification.aspx. 
Accessed 15 August 2012. 
24. World Health Organization. International Classification of Diseases (ICD). 
http://www.who.int/classifications/icd/en. Accessed 24 December 2012. 
25. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental 
Disorders, Text Revision (DSM-IV-TR). 4th edn. American Psychiatric Association, 
Washington, DC. 
26. Cantwell DP (1996) Attention deficit disorder: a review of the past 10 years. J Am Acad 
Child Adolesc Psychiatry 35 (8):978-987. doi:10.1097/00004583-199608000-00008 
27. Rucklidge JJ, Tannock R (2002) Validity of the Brown ADD scales: an investigation in a 
predominantly inattentive ADHD adolescent sample with and without reading 
disabilities. J Atten Disord 5 (3):155-164. 
ADHD Data Inventory manuscript draft version 2.2: 24/12/2012 
Page 19 of 26 
28. Goodman R. (1997) The Strengths and Difficulties Questionnaire: A Research Note. J 
Child Psychol Psychiatry 38:581-586. 
29. Panei P, Arcieri R, Bonati M, Bugarini M, Didoni A, Germinario E (2010) Safety of 
psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. 
Adverse Drug Reaction Bulletin (260):999-1002. 
30. Didoni A, Sequi M, Panei P, Bonati M. One-year prospective follow-up of 
pharmacological treatment in children with attention-deficit/hyperactivity disorder. 
(2011) Eur J Clin Pharmacol 67: 1061-1067. 
31. Arcieri R, Germinario EAP, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, 
the Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers. 
(2012)  Cardiovascular Measures in Children and Adolescents with Attention-
Deficit/Hyperactivity Disorder Who Are New Users of Methylphenidate and 
Atomoxetine. J Child Adolesc Psychopharmacol 22: 423-431. 
32. McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, 
Taylor E, Williams T, Wong ICK. (2009) Attention-deficit hyperactivity disorder: 
treatment discontinuation in adolescents and young adults. Br J Psychiatry 194:273-
277. 
33. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. (2012) The 
epidemiology of pharmacologically treated attention deficit hyperactivity disorder 
(ADHD) in children, adolescents and adults in UK primary care. BMC Pediatrics 12(1):78. 
Epub. 
34. Kurth BM, Kamtsiuris P, Hölling H, Schlaud M, Dölle R, Ellert U, et al.  (2008) The 
challenge of comprehensively mapping children's health in a nation-wide health survey: 
design of the German KiGGS-Study. BMC Public Health 8:196. 
35. Huss M, Hölling H, Kurth BM, Schlack R. (2008) How often are German children and 
adolescents diagnosed with ADHD? Prevalence based on the judgment of health care 
professionals: results of the German health and examination survey (KiGGS). Eur Child 
Adolesc Psychiatry 17 Suppl 1:52-58. 
36. Ehrenstein V, Antonsen S, Pedersen L. (2010) Existing data sources for clinical 
epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2:273-279. 
ADHD Data Inventory manuscript draft version 2.2: 24/12/2012 
Page 20 of 26 
37. WHO. (2012) International Classification of Primary Care, Second edition (ICPC-2). 
http://www.who.int/classifications/icd/adaptations/icpc2/en/index.html. Accessed 15 
August 2012. 
38. Sturkenboom M, Nicolosi A, Cantarutti L, Mannino S, Picelli G, Scamarcia A, Giaquinto C, 
NSAIDs Paediatric Research Group. (2005) Incidence of mucocutaneous reactions in 
children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or 
nonopioid analgesics. Pediatrics 116;e26-33. 
39. Lindemann C, Langner I, Kraut A, Banaschewski T, et al (2012). Age-specific prevalence, 
incidence of new diagnoses and drug treatment of attention-deficit/hyperactivity 
disorder in Germany. J Child Adolesc Psychopharmacol 22: 307-314. 
40. Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, 
Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M; EU-ADR Consortium. 
(2011) Combining electronic healthcare databases in Europe to allow for large-scale 
drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20(1):1-11.  
 
ADHD Data Inventory manuscript draft version 2.2: 24/12/2012 
Page 21 of 26 
Figure 1: Survey and database assessment schematic flowchart 
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Table 1: Databases identified and invited to participate in the survey 
Country Purpose 
of 
database 
Database Website 
Re
sp
on
se
 Information 
from 
websites & 
literature 
Denmark PM National Psychiatric Central 
Register 
www.psykiatriskforskning.
dk/research/central-
research-register/ 
Yes No 
Denmark PM/ 
Admin 
Odense Pharmacoepidemiological 
Database 
www.sdu.dk Yes No 
Denmark PM/ 
Admin 
Aarhus University Prescription 
Database 
kea.au.dk/en/informaticsa
ndstatistics/researchdatab
ases/theprescriptiondatab
ases/ 
Yes No 
Denmark RC The Danish National Birth Cohort 
(DNBC) 
www.dnbc.dk/ Yes No 
Finland PM/ 
Admin 
Prescription register www.kela.fi No Yes 
Finland RC The Finnish Northern Finland Birth 
Cohort (NFBC) 1986 study 
kelo.oulu.fi/NFBC/ No Yes 
Germany RC The German Health Interview and 
Examination Survey for Children 
and Adolescents (KiGGS) 
www.rki.de Yes No 
Germany PM The German Population Based 
Long Term Follow-up of ADHD 
www.bips.uni-bremen.de No Yes 
Italy PM Pedianet www.pedianet.it/ No Yes 
Italy PM Sistema Informativo Sanitario 
Regionale Database-FVG region 
www.regione.fvg.it No No 
Italy PM Health Search Database Thales - 
CSD LPD (HSD) 
www.healthsearch.it/ Yes No 
Italy PM Tuscany Regional database www.arsanita.toscana.it No No 
Italy PM Lombardy Regional ADHD database http://givitiweb.marionegr
i.it/Centers/Public/ADHD/
Default.aspx 
Yes No 
Italy PM ARNO Observatory osservatorioarno.cineca.or
g/arnoeng.htm 
No No 
Italy PM The National ADHD Registry http://www.farmaco-
iss.org/ 
Yes No 
Netherlands PM Integrated Primary Care 
Information Database (IPCI) 
www.ipci.nl No Yes 
Netherlands PM PHARMO-Record-Linkage-System www.pharmo.nl Yes No 
Netherlands PM InterAction database www.iadb.nl Yes No 
Netherlands RC The Dutch KOALA Birth Cohort 
Study 
http://www.koala-study.nl Yes No 
Netherlands RC The Dutch TRAILS study  No No 
Netherlands RC The Dutch Generation R study www.generationr.nl/ Yes No 
Norway PM The Norwegian Prescription 
Database 
www.norpd.no/ Yes No 
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Country Purpose 
of 
database 
Database Website 
Re
sp
on
se
 Information 
from 
websites & 
literature 
Portugal RC Centro de Estudos e Avaliação em 
Saúde (Centre for Health Studies 
and Evaluation) (CEFAR) 
 No No 
Sweden PM Swedish Medical Birth Register www.socialstyrelsen.se Yes No 
Sweden PM Swedish National Health Data 
Registers 
www.socialstyrelsen.se Yes No 
Sweden RC The Swedish All Babies in 
Southeast Sweden 
www.abis-studien.se/ No No 
Spain PM Base de datos para la Investigacion 
Farmacoepidemiologica en 
Atencion Primaria (BIFAP) 
www.bifap.org/ No No 
UK PM General Practice Research 
Database (GPRD) (now part of 
Clinical Practice Research Datalink) 
www.cprd.com/ Yes No 
UK PM The Health Improvement Network 
Data (THIN) 
csdmruk.cegedim.com/ Yes No 
UK PMS Prescription Event Monitoring 
(PEM) 
www.dsru.org/pem Yes No 
UK Admin Prescription Pricing Authority (PPA) www.nhsbsa.nhs.uk/Presc
riptionServices.aspx 
No No 
UK PM QResearch www.qresearch.org/ Yes No 
UK PM Scottish Programme for Improving 
Clinical Effectiveness in Primary 
Care (SPICE) formerly known as 
GPASS (General Practice 
Administration System for 
Scotland) 
http://www.abdn.ac.uk/ia
hs/uploads/files/PCI.pdf 
No No 
UK PM Medicines Monitoring Unit 
(MEMO)  
www.dundee.ac.uk/memo
/ 
No No 
UK RC The Avon Longitudinal Study of 
Parents and Children (ALSPAC) 
www.bristol.ac.uk/alspac/ Yes No 
UK RC The 1970 British Cohort Study www.cls.ioe.ac.uk/bcs70 No Yes 
UK RC The Millennium Cohort Study  www.cls.ioe.ac.uk/mcs No Yes 
UK RC The 2004 British Child and 
Adolescent Mental Health Survey 
 No No 
UK RC The Scottish SEATON Study www.abdn.ac.uk/seatonst
udy/ 
Yes No 
European RC The ADHD Observational Research 
in Europe 
 No No 
European RC The International Muti-Center 
ADHD Genetics (IMAGE) Project 
 No No 
UK, France, 
Germany 
PM IMS Disease Analyzer (IMS DA) www.imshealth.com/ Yes No 
PM: Patient management and/or disease surveillance; RC: Research cohort; Admin: administrative database 
for reimbursement and/or renumeration of prescriptions; PMS: post-marketing surveillance 
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Table 2: Detailed information of the participating databases which record ADHD diagnoses 
Name of Database Aarhus DNBC 
National 
Psychiatric Central 
Register 
KiGGS HSD 
Italian ADHD 
Register 
Lombardy Region 
ADHD Database 
Generation R 
Study 
KOALA 
Swedish National 
Health Data 
Registers 
ALSPAC GPRD THIN QResearch IMS DA 
Country Denmark Denmark Denmark Germany Italy Italy Italy Netherlands Netherlands Sweden UK UK UK UK 
UK, France and 
Germany 
Type of database 
Prescription 
Information 
Databases
a
 
Longitudinal/ 
Patient Record 
Database 
Longitudinal/ 
Patient Record 
Database
a
 
Cross-
sectional, 
Observational 
Data Survey 
Longitudinal/ 
Patient Record 
Database 
ADHD specific 
patient cohort 
ADHD specific 
patient cohort 
Longitudinal/ 
Patient Record 
Database 
Longitudinal/ 
Patient Record 
Database 
Longitudinal/ 
Patient Record 
Database* 
Longitudinal/ 
Patient Record 
Database 
Longitudinal/ 
Patient Record 
Database 
Longitudinal/ 
Patient Record 
Database 
Longitudinal/ 
Patient Record 
Database 
Longitudinal/ 
Patient Record 
Database 
Number of Investigators N/A N/A N/A 5 700 84 18 5 3 N/A 1 600 495 600 >100 
Starting year 1994 1996 1969 2003 1996 2007 2007 2002 2000 2005 1990 1987 2003 1990 1991 
End year ongoing ongoing ongoing 2006 ongoing ongoing ongoing ongoing ongoing ongoing ongoing ongoing ongoing ongoing ongoing 
E
s
ti
m
a
te
d
  
N
o
. 
Male (no. Of 
ADHD) 
10,000 (50) 48,000 (N/A) 
633,385 (N/A) 
8,985 (710) 760,000 (114) 2,000 201 3,000 (N/A) 1,400 (N/A) 32,000 (N/A) 5,000 (N/A) 
2,000,000 
(12,000) 
1,713,823 
(N/A) 
200,000 (N/A) 2,500,000 (N/A
c
) 
Female (no. of 
ADHD) 
10,000 (0) 46,000 (N/A) 8,656 (156) 850,000 (20) 244 28 3,000 (N/A) 1,400 (N/A) 18,000 (N/A) 5,000 (N/A) 
2,000,000 
(8,000) 
1,750,216 
(N/A) 
200,000 (N/A) 2,500,000 (N/A
c
) 
P
re
s
c
ri
p
ti
o
n
s
 
Medication Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Medication Code ATC ATC ATC ATC ATC ATC 
Only atomoxetine 
and 
methylphenidate 
N/A 
Not yet 
determined
b
 
ATC ATC Multilex ATC, Multilex 
EMIS drug 
database 
ATC, Read 
Indication  No No No Yes Yes Yes Yes N/A No No Yes Yes No No Yes 
Dosage Yes Yes No Yes Yes Yes Yes N/A Yes Yes No Yes Yes Yes Yes 
Duration Yes Yes No Yes Yes Yes Yes N/A Yes No Yes Yes Yes Yes Yes 
O
u
tc
o
m
e
s
/C
o
n
fo
u
n
d
e
rs
 
Weight No Yes No Yes Yes Yes Yes Yes
d
 Yes No Yes Yes Yes No Yes 
Height No Yes No Yes Yes Yes Yes Yes
d
 Yes No Yes Yes Yes No Yes 
Blood pressure No No No Yes Yes Yes Yes Yes
d
 Yes No Yes Yes Yes No Yes 
Heart rate No No No Yes No Yes Yes Yes
d
 Yes No Yes Yes Yes No Yes 
Medical diagnosis Yes
a
 Yes Yes Yes Yes Yes Yes Yes
d
 Yes Yes Yes Yes Yes Yes Yes 
Symptoms/clinical 
events 
Yes
a
 Yes Yes Yes Yes Yes Yes Yes
d
 Yes No Yes Yes Yes No Yes 
Diagnoses/clinical 
events code  
ICD-10 ICD-10 ICD-10, ICD-8 
parent 
reported 
clinician based 
information on 
ADHD 
ICD-9CM MedDRA list of co-morbidities N/A 
Not yet 
determined
b
 
ICD-10 
ICD-10, 
ALSPAC 
generated 
Read Read Read ICD-10, Read 
validation of 
ADHD diagnosis 
via  
N/A 
Comparison  
with SDQ 
ICD-10 
Comparison 
with SDQ 
ICD9-CM and 
further 
validation 
required 
DSM-IV DSM-IV 
CBCL &  
DSM-IV
e
 
Not yet 
determined
b
 
Uncertain 
Traits and 
DAWBA 
questionnaire 
GP 
questionnaires 
GP 
questionnaires 
None None 
Medical 
examinations 
Yes No Yes Yes Yes Yes Yes Yes
d
 No No No Yes Yes No Yes 
Ethnicity Yes No Yes Yes No No No Yes
d
 Yes Yes Yes Yes No Yes Yes 
Genetic 
information 
No Yes Yes No No No No Yes
d
 No No Yes No No No No 
D
a
ta
 a
c
c
e
s
s
 
via academic 
collaboration 
N/A Yes Yes Yes Yes No Yes Yes
d
 Yes Yes Yes Yes No No Yes 
by paying a fee N/A Yes No Yes Yes Yes Yes No
d
 Yes Yes Yes Yes Yes Yes Yes 
a: Linkable to other registries through unique identifiers of the patients; b: Future follow-up in 2012; N/A: Not available; c: the number of ADHD patients can be supplied on personal request; d: from 
Jaddoe et al. (2010); e: from Ghassabian et al. (2012). ATC = Anatomical Therapeutic Chemical classification system; CBCL: Child Behavior Checklist ; DAWBA: Development and Well-Being 
Assessment; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4
th
 edition; GP: General Practitioner ; ICD: International Classification of Diseases; MedDRA: Medical Dictionary for 
Regulatory Activities; Read: Read Clinical Terms; SDQ: Strengths and Difficulties Questionnaire. 
Tabel met opmaak
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Table 3: Detailed information obtained from literature and websites of non-responding databases 
Name of Database 
Prescription 
Register 
The Finish Northern 
Finland Birth Cohort 
(NFBC) 1986 study 
The German 
Population Based 
Long Term Follow-
up of ADHD Pedianet 
Integrated Primary 
Care Information 
Database (IPCI) 
The 1970 British 
Cohort Study 
The Millennium 
Cohort Study 
Country Finland Finland Germany Italy Netherlands UK UK 
Type of database 
Prescription 
Information 
Database 
Longitudinal one-
year birth cohort 
Longitudinal/Patient 
Record Database 
Longitudinal/Patien
t Record Database 
Longitudinal/Patient 
Record Database 
Longitudinal study Longitudinal study 
Number of Investigators N/A N/A N/A 300s GPs 150 GPs N/A N/A 
Starting year 1994 1985 2010 1998 1992 1970 2000 
End year ongoing 1986 ongoing ongoing ongoing ongoing ongoing 
Estimated No. of 
individuals 
480,000  
(0-18 years) 
9,400 30,000 
106,554  
(0-14 years)
a
 
>1,000,000 (161,108 
of 0-18 years)
b
 
15,500 18,800 
P
re
s
c
ri
p
ti
o
n
s
 
Medication Code ATC N/A N/A ATC ATC N/A N/A 
Indication of 
prescription 
limited N/A N/A No Yes N/A N/A 
Dosage of 
prescription 
limited N/A N/A Yes Yes N/A N/A 
Duration of 
prescription 
No N/A N/A Yes Yes N/A N/A 
O
u
tc
o
m
e
s
/C
o
n
fo
u
n
d
e
rs
 
Weight No N/A N/A Yes Yes Yes Yes 
Height No N/A N/A Yes Yes Yes Yes 
Blood pressure No Yes N/A N/A Yes N/A N/A 
Heart rate No Yes N/A N/A N/A N/A N/A 
Medical diagnosis No limited N/A Yes Yes N/A N/A 
Symptoms/clinical 
events 
No limited N/A Yes Yes limited limited 
Diagnoses/clinical 
events code  
N/A N/A N/A N/A ICPC N/A N/A 
ADHD diagnosis 
tool 
N/A N/A N/A N/A N/A N/A N/A 
Medical 
examinations 
No limited N/A Yes Yes limited limited 
Ethnicity N/A N/A N/A N/A N/A N/A N/A 
Genetic 
information 
N/A N/A N/A N/A N/A N/A N/A 
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Name of Database 
Prescription 
Register 
The Finish Northern 
Finland Birth Cohort 
(NFBC) 1986 study 
The German 
Population Based 
Long Term Follow-
up of ADHD Pedianet 
Integrated Primary 
Care Information 
Database (IPCI) 
The 1970 British 
Cohort Study 
The Millennium 
Cohort Study 
D
a
ta
 
a
c
c
e
s
s
 via academic 
collaboration 
N/A N/A N/A N/A N/A N/A N/A 
by paying a fee N/A N/A N/A N/A N/A N/A N/A 
N/A=not available; GPs=General Practices; ICPC=The International Classification of Primary Care; a=in year  2008, b=in year 2004 
 
